CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Drug Toxicology Testing — Qualitative (Presumptive) and Quantitative (Definitive) Coverage Criteria

Defines coverage, documentation, coding, and limitations for qualitative (immunoassay/presumptive) and quantitative (definitive/confirmatory) drug toxicology tests for Neighborhood Health Plan lines of business.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyDrug Toxicology Testing — Qualitative and Quantitative

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJan 1, 2023

Next Review DateN/A

Key ActionQuantitative testing must be ordered individually by the treating medical provider at time of order and specify the drug to be confirmed.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 unit/daytesting limited to one unit per day per test type

Qualitative & Quantitativetwo test types covered

Medicaid, INTEGRITY, Commerciallines of business this policy applies to

CPT/HCPCS listedspecific billable codes enumerated in policy

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Qualitative (Presumptive) Coverage

Covered when ANY of the following apply:

Qualitative coverage: A member is receiving treatment for chronic pain with prescription opioid or other medication associated with increased risk for misuse or addiction; OR a member is undergoing treatment for substance use disorder or is otherwise requiring monitoring for use/misuse of controlled or illicit substance(s); OR misuse of prescribed or illicit substances is suspected; OR a member is beginning a pain management program or substance use disorder treatment program.

Qualitative testing may be performed on urine, blood, or saliva; urine is preferred for broad screening.

inv-02: Quantitative (Definitive) Coverage

Covered when ANY of the following apply (examples):

Quantitative coverage: Unexpected positive test inadequately explained by the patient; OR unexpected negative test (suspected medication diversion); OR need for quantitative levels to compare with established benchmarks for clinical decision making.

Quantitative testing must be ordered individually by the treating medical provider at the time of order, specified for the particular drug to be confirmed, may not be ordered by standing orders, and must be performed in a laboratory.

Coverage excludes testing performed for medico-legal or employment purposes (for example, court-ordered drug screening or pre‑employment/continued employment screening) and testing ordered solely to meet third‑party requirements. Separate billing for specimen validity checks performed as part of urine drug testing (e.g., pH, specific gravity, creatinine, oxidants, nitrates) is not allowed; these are considered internal specimen validation and should not be billed separately. Additionally, testing that is included in an all‑inclusive bundled rate for a substance use disorder program is not eligible for separate reimbursement.

All services paid under this policy must meet medical necessity requirements and applicable documentation standards. Routine testing at every visit and duplicate testing of the same drug using multiple specimen types simultaneously (for example urine and blood) are limited and may be denied as not reasonable or necessary.

Routine drug testing at every visit is considered not reasonable or necessary and is not eligible for reimbursement. When a qualitative (presumptive) immunoassay test sufficiently answers the clinical question (for example, to monitor adherence or detect presence of a drug class), performing a quantitative (definitive/confirmatory) test is not covered solely for routine surveillance.

Quantitative testing should be reserved for situations that require identification of a specific drug or measurement of levels to guide clinical decision‑making (for example, an unexpected positive or negative result). The policy also clarifies a frequency limit of 1 unit per day per test type, so clinicians should order tests accordingly and document why a quantitative test is clinically necessary when it is selected instead of a qualitative screen.

inv-15: Covered Indications

Covered indications: Monitoring patients on chronic opioid or other high-risk medications; treatment and monitoring of substance use disorder; suspected misuse or diversion; initiation of pain management or substance use disorder treatment programs.

These indications apply to qualitative (presumptive) testing and to quantitative (definitive) testing when clinically indicated as described in quantitative coverage criteria.

Coding and Billing Codes

Covered CPT Codes - Presumptive/QualitativeCPTCovered

80305	Drug test(s), presumptive, any number of drug classes; devices read by direct optical observation only; includes sample validation when performed, per date of service.
80306	Drug test(s), presumptive, any number of drug classes, qualitative, devices or procedures by instrument chemistry analyzers; includes sample validation when performed, per date of service.
80307	Drug test(s), presumptive, any number of drug classes, qualitative, devices or procedures by instrument chemistry analyzers; includes sample validation when performed, per date of service.

Covered HCPCS Codes - Definitive/QuantitativeHCPCSCovered

G0480	Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish structural isomers; qualitative or quantitative; includes specimen validity testing, per day, 1-7 drug class(es).
G0481	Drug test(s), definitive; includes specimen validity testing, per day, 8-14 drug class(es).
G0482	Drug test(s), definitive; includes specimen validity testing, per day, 15-21 drug class(es).
G0483	Drug test(s), definitive; includes specimen validity testing, per day, 22 or more drug class(es).
G0659	Drug test(s), definitive, performed without method- or drug-specific calibration or internal standards; includes specimen validity testing, per day, any number of drug classes.

Drug class counts for HCPCS — mapping of codes to drug-class ranges

G04801-7 drug class(es) per day

G04818-14 drug class(es) per day

G048215-21 drug class(es) per day

G048322 or more drug class(es) per day

G0659Any number of drug classes per day (performed without method- or drug-specific calibration/internal standards)

Provider Actions and Documentation Requirements

Documentation Required

Quantitative testing ordering requirements

Quantitative testing must be ordered on an individual basis by the medical provider directly caring for the member at the time the order is placed. Orders may not be standing or routine orders (e.g., scheduled testing at every visit). Quantitative tests must specify the specific drug(s) to be confirmed (not a broad comprehensive confirmatory panel) and must be performed in a laboratory.

Order must be placed by provider directly caring for the member at time of order
May not be ordered as standing/routine orders
Order must indicate specific drug(s) to be confirmed
Must be performed in a laboratory

Denial Risk

Quantitative testing not covered in certain situations

Quantitative testing is not covered when qualitative (presumptive) testing is clinically appropriate and meets clinical needs, nor is routine quantitative testing (e.g., testing at each visit) covered. Routine confirmatory testing without an unexpected positive or negative finding and testing requested solely to meet a third party’s requirements are also not eligible for reimbursement.

Routine quantitative testing (testing at each visit) not eligible
Not covered when qualitative testing is clinically appropriate
Routine confirmatory testing without an unexpected result not eligible
Testing ordered solely to meet third‑party requirements not eligible

Documentation Required

Documentation and claims requirements

Providers must document medical necessity per payer criteria and submit claims with complete coding and supporting documentation. All services must be medically necessary to qualify for reimbursement; Neighborhood may reference NCDs, LCDs, industry-accepted criteria (e.g., InterQual), EOHHS recommendations, and Clinical Medical Policies when determining medical necessity. Claims must follow CPT, ICD-10-CM, and HCPCS coding standards and be submitted within contractual timely filing guidelines.

Document medical necessity referencing applicable criteria (NCD/LCD/InterQual/CMP/EOHHS)
Include complete coding per CPT, ICD-10-CM, HCPCS
Submit supporting documentation to justify quantitative testing
Adhere to timely filing and contractual requirements

Denial Risk

Medico-legal and employment testing not covered

Drug screening for medico-legal purposes (for example, court-ordered testing) or for employment purposes (such as pre-employment or continued-employment requirements) is not covered and may be denied.

Medico-legal (court-ordered) testing not covered
Employment-related testing (pre-employment or continuation) not covered

Not Covered Services

Not covered under this policy: testing performed for medico-legal or employment reasons (including court‑ordered screening and employer-mandated tests) and tests ordered solely to satisfy third‑party requirements. These services may be denied.

Routine testing at every visit — whether qualitative or quantitative — is not eligible for reimbursement. Tests that are included within an all‑inclusive substance use disorder program rate are not separately billable. Providers must not separately bill specimen validity procedures performed as internal controls of urine drug testing (e.g., pH, specific gravity, creatinine, oxidants, nitrates); these validity checks are not separately reportable.

Background

Qualitative (presumptive) drug screens are screening immunoassays that detect the presence of drug classes rather than specific molecular entities. They are commonly performed on urine, blood, or saliva, with urine preferred for broad screening. These tests are used for monitoring patients on chronic opioid or other high‑risk medications, for patients in substance use disorder treatment, when misuse or diversion is suspected, or at initiation of pain management or SUD programs.

Quantitative (definitive/confirmatory) testing identifies specific drugs and can provide measured concentrations when that information is necessary for clinical decision‑making. Quantitative tests must be performed in a laboratory and ordered by the treating medical provider with the specific drug to be confirmed; they are not appropriate as routine screening when a qualitative test would meet clinical needs.

Definitions

Qualitative (Presumptive) testing — definition

DefinitionPresumptive (qualitative) testing: screening/immunoassay tests that detect the presence of drug classes (e.g., urine, blood, saliva) used for monitoring in pain management or SUD treatment and when misuse is suspected.

Typical methodsImmunoassay, chemical spot tests; commonly performed on urine (preferred for broad screening), blood, or saliva

PurposeInitial screen to detect presence of drug classes; not definitive for specific substances

Quantitative (Definitive/Confirmatory) testing — definition

DefinitionDefinitive/confirmatory (quantitative) testing: tests performed in a laboratory that identify specific substances and may provide quantitation for clinical decision-making.

Ordering requirementsMust be ordered individually by the treating medical provider with the specific drug indicated; not allowed from standing orders

Methods/codesIncludes definitive methods (e.g., GC/MS, LC/MS) represented by HCPCS codes G0480–G0483 and G0659

OpenPayer